Results 31 to 40 of about 50,512 (171)

Discovery of new nicotinamides as apoptotic VEGFR-2 inhibitors: virtual screening, synthesis, anti-proliferative, immunomodulatory, ADMET, toxicity, and molecular dynamic simulation studies

open access: yesJournal of Enzyme Inhibition and Medicinal Chemistry, 2022
A library of modified VEGFR-2 inhibitors was designed as VEGFR-2 inhibitors. Virtual screening was conducted for the hypothetical library using in silico docking, ADMET, and toxicity studies. Four compounds exhibited high in silico affinity against VEGFR-
Reda G. Yousef   +9 more
doaj   +1 more source

Differential expression of Vegfr-2 and its soluble form in preeclampsia.

open access: yesPLoS ONE, 2012
BackgroundSeveral studies have suggested that the main features of preeclampsia (PE) are consequences of endothelial dysfunction related to excess circulating anti-angiogenic factors, most notably, soluble sVEGFR-1 (also known as sFlt-1) and soluble ...
Carine Munaut   +10 more
doaj   +1 more source

In Silico Evaluation of Interactions of Triterpenes in Momordica charantia on Proteins Involved in Angiogenesis

open access: yesProceedings, 2019
Angiogenesis is important process that play active role in tumorigenesis. VEGFR-1, a member of the tyrosine kinase receptor family, is known as the receptor for VEGF ligands in tumor cells.
Büşra Sevim, Onur Eroğlu
doaj   +1 more source

Single nucleotide polymorphisms: rs833061, rs699947, and rs35569394, and the expression of the vascular endothelial growth factor gene in Moroccan patients with lung cancer [PDF]

open access: yesExploration of Medicine
Aim: Angiogenesis is a universal hallmark of all cancers involving a variety of proteins including vascular endothelial growth factor (VEGF). Extensive studies have explored the potential implications of single nucleotide polymorphisms (SNPs) within VEGF-
Younes El Founini   +9 more
doaj   +1 more source

Altered expression of vascular endothelial growth factor, vascular endothelial growth factor receptor-1, vascular endothelial growth factor receptor-2, and Soluble Fms-like Tyrosine Kinase-1 in peripheral blood mononuclear cells from normal and preeclamptic pregnancies

open access: yesChinese Journal of Physiology, 2019
Preeclampsia (PE) is the leading cause of maternal and fetal morbidity and mortality. It complicates around 2%–10% pregnancies worldwide due to imbalance between proangiogenic and anti-angiogenic factors, leading to incomplete placentation, ischemia, and
Zaima Ali   +4 more
doaj   +1 more source

VEGF, VEGFR-1 and VEGFR-2 immunoreactivity in the porcine arteries of vascular subovarian plexus (VSP) during the estrous cycle.

open access: yesFolia Histochemica et Cytobiologica, 2006
: Vascular endothelial growth factor (VEGF) is an important angiogenic factor in the female reproductive tract. It binds to cell surface through ligand-stimulatable tyrosine kinase receptors, the most important being VEGFR-1 (flt-1) and VEGFR-2 (flk-1 ...
A Andronowska   +4 more
doaj   +1 more source

The role of the FLT1 gene alternative splicing in the fetal growth retardation development

open access: yesActa Biomedica Scientifica
Background. Fetal growth restriction (FGR) is a major pregnancy complication often associated with placental dysfunction and angiogenic imbalance. The FLT1 gene encodes VEGFR-1, producing both membrane receptors and soluble isoforms (sFlt-1) through ...
M. M. Gavrilenko   +5 more
doaj   +1 more source

The Effects of VEGF Signal Pathway on Etiopathogenesis and AntiVEGF Treatments in Childhood Cancers

open access: yesÇocuk Dergisi, 2023
Vascular endothelial growth factor (VEGF) is the most physiologically and pathologically potent angiogenic factor that acts directly on endothelial cells.
Ali Kazdal   +3 more
doaj   +1 more source

Mediating EGFR-TKI Resistance by VEGF/VEGFR Autocrine Pathway in Non-Small Cell Lung Cancer

open access: yesCells, 2022
NSCLC treatment includes targeting of EGFR with tyrosine kinase inhibitors (TKIs) such as Erlotinib; however, resistance to TKIs is commonly acquired through T790M EGFR mutations or overexpression of vascular endothelial growth factor receptor-2 (VEGFR-2)
Chike Osude   +11 more
doaj   +1 more source

Osimertinib resistance in non‐small cell lung cancer is mediated by sustained AKT activation through lipid raft‐dependent insulin signaling

open access: yesMolecular Oncology, EarlyView.
Osimertinib is effective against EGFR‐mutant NSCLC, but resistance often develops. We found that increased cholesterol in lipid rafts, specialized regions of the cell membrane, promotes recruitment of the scaffold protein FLOT1 and insulin receptors.
Yen‐Lin Lai   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy